Evidence map›Paper›PMID 42853241›Full record

ArticleNeuroradiology2026

Accelerated hippocampal atrophy in APOE ε4 homozygotes and females: Longitudinal findings from the Tohoku Medical Megabank MRI study.

Shunji Mugikura, Naoko Mori, Megumi Satake, Ippei Chiba, Makiko Taira, Takuya Koyama, Tomomi Onuma, Tomo Saito, Masato Takase, Ikuko N Motoike and 19 more

Abstract read
PubMed Publisher
In one paragraph

Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Shunji MugikuraTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan. shunji.mugikura.d3@tohoku.ac.jp.ORCID https://orcid.org/0000-0002-9138-610X
Naoko MoriTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Megumi SatakeGraduate School of Medicine, Tohoku University, Sendai, Japan.
Ippei ChibaGraduate School of Medicine, Tohoku University, Sendai, Japan.
Makiko TairaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Takuya KoyamaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Tomomi OnumaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Tomo SaitoTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Masato TakaseGraduate School of Medicine, Tohoku University, Sendai, Japan.
Ikuko N MotoikeTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Takanori HidakaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Akihito OtsukiTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Masatsugu OruiTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Taku ObaraTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Fuji NagamiTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Naoki NakayaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Soichi OgishimaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Kazuki KumadaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Fumiki KatsuokaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Seizo KoshibaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Yasuyuki TakiInstitute of Development, Aging and Cancer (IDAC), Tohoku University, Sendai, Japan.
Ritsuko ShimizuGraduate School of Medicine, Tohoku University, Sendai, Japan.
Shinichi KuriyamaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Kinuko OhnedaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Yoko IzumiTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Nobuo FuseTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Atsushi HozawaGraduate School of Medicine, Tohoku University, Sendai, Japan.
Kengo KinoshitaTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan.
Masayuki YamamotoTohoku Medical Megabank Organization, Tohoku University, Sendai, Japan. masayuki.yamamoto.c7@tohoku.ac.jp.

Funding

JSPS KAKENHI 24K06543, 25K10609Medical Research and Development (AMED) JP23dm0307003h0006Medical Research and Development (AMED) JP 25tm0524003h0003the Reconstruction Agency; the Ministry of Education, Culture, Sports, Science and Technology (MEXT); and the Japan Agency for Medical Research and Development (AMED) JP21km0105001, JP21km0105002, JP23dm0307003h0006, JP24tm0524003h0002
6 · The paper itself

Abstract

purposeThe apolipoprotein E ε4 allele is a major genetic risk factor for Alzheimer's disease, but its longitudinal effect on hippocampal atrophy is unclear. Selective hippocampal atrophy, defined as greater hippocampal volume (HpV) loss relative to total brain volume (TBV), is an early marker of preclinical Alzheimer's disease. We examined age-related effects of APOE ε4 on longitudinal hippocampal atrophy in a large population-based cohort.

methodsWe analyzed MRI data from 9,453 adults in the Tohoku Medical Megabank MRI Study, including 5,774 participants with follow-up MRI after a mean interval of 4.7 years. Cross-sectional analyses used linear regression to assess HpV and TBV, adjusting for age, sex, APOE genotype, and intracranial volume. Longitudinal analyses assessed HpV-Ratio and TBV-Ratio, defined as the second MRI volume divided by the first volume, using regression models including age, sex, APOE genotype, MRI interval, and interaction terms between age and APOE genotype and between age and sex. Montreal Cognitive Assessment (MoCA) scores obtained at the second MRI were included to assess effects independent of cognition.

resultsNo significant APOE genotype effects were observed in cross-sectional analyses. Longitudinally, ε4/ε4 carriers showed greater decline in HpV-Ratio than ε3/ε3 and ε3/ε4 carriers, and females showed lower HpV-Ratio than males. No APOE genotype or sex main effects were observed for TBV-Ratio. Interactions between age and APOE genotype and between age and sex demonstrated age-related acceleration of HpV-Ratio decline in ε4/ε4 carriers and females, and these effects persisted after adjustment for MoCA scores.

conclusionAPOE ε4 homozygosity and female sex accelerate selective hippocampal atrophy in population-based cohorts.

Indexed as

AgingAlzheimer’s diseaseApolipoprotein ε4HippocampusLongitudinal MRISex factors

Identifiers

PMID42853241

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.